Research graph
References from Is bridging or slow ramp‐up necessary in patients with high tumour load prior to epcoritamab?. Local targets link to admitted publications; unresolved targets remain external evidence.
Clinical management of bispecific antibody therapy for lymphoma: a British Society for Haematology Good Practice Paper
10.1111/bjh.70018 · 2025 · External reference
Outcomes of bispecific antibodies after CAR T‐cell failure for large B‐cell lymphoma: results from the ABC consortium
10.1182/bloodadvances.2025016968 · 2026 · External reference
Real world safety outcomes of an outpatient lymphoma bispecific antibody program: a single center experience from Johns Hopkins
2025 · External reference
Predictive factors and nomogram for the risk of cytokine release syndrome with anti‐CD3 × CD20 bispecific antibodies for Chinese patients
2025 · External reference
